Erratum: Probiotic Bacteria Produce Conjugated Linoleic Acid Locally in the Gut That Targets Macrophage PPAR γ to Suppress Colitis (PLoS ONE (2012) 7:2 (e31238) DOI: 10.1371/journal.pone.0031238);Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Bassaganya Riera, Josep ^a   Viladomiu, Monica ^a   Pedragosa, Mireia ^a   de Simone, Claudio ^b   Carbo, Adria ^a   Shaykhutdinov, Rustem ^d   Jobin, Christian ^c   Arthur, Janelle C ^c   Corl, Benjamin A ^f   Vogel, Hans ^d   Storr, Martin ^d,e   Hontecillas, Raquel ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED LINOLEIC ACID; DOCUSATE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; DEXTRAN SULFATE; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CELL; BONE MARROW CELL; CELL FUNCTION; CELL PROTECTION; COLITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TARGETING; FECES ANALYSIS; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOMODULATION; LAMINA PROPRIA; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MESENTERY LYMPH NODE; MICROBIAL DIVERSITY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPLETION; SPLEEN CELL; TISSUE SECTION; ANIMAL; BACTERIUM; BIODIVERSITY; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; COLON; DISEASE MODEL; DRUG EFFECT; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; METABOLISM; METABOLOMICS; PATHOLOGY;

ANIMALS; BACTERIA; BIODIVERSITY; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; LINOLEIC ACIDS, CONJUGATED; LYMPH NODES; MACROPHAGES; METABOLOMICS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PPAR GAMMA; PROBIOTICS; PROTECTIVE AGENTS;

EID: 84857381354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0275513     Document Type: Erratum

References (39)

1. Papadakis KA, Targan SR, (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298.
2. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127: 777-791.
3. Crawford PA, Gordon JI, (2005) Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci U S A 102: 13254-13259.
4. Bassaganya-Riera J, Hontecillas R, Beitz DC, (2002) Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 21: 451-459.
5. Serini S, Piccioni E, Merendino N, Calviello G, (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14: 135-152.
6. O'Shea M, Bassaganya-Riera J, Mohede IC, (2004) Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 79: 1199S-1206S.
7. Hofmanova J, Ciganek M, Slavik J, Kozubik A, Stixova L, et al. (2011) Lipid alterations in human colon epithelial cells induced to differentiation and/or apoptosis by butyrate and polyunsaturated fatty acids. J Nutr Biochem.
8. Clarke JM, Topping DL, Christophersen CT, Bird AR, Lange K, et al. (2011) Butyrate esterified to starch is released in the human gastrointestinal tract. Am J Clin Nutr.
9. Bassaganya-Riera J, Hontecillas-Magarzo R, Bregendahl K, Wannemuehler MJ, Zimmerman DR, (2001) Effects of dietary conjugated linoleic acid in nursery pigs of dirty and clean environments on growth, empty body composition, and immune competence. J Anim Sci 79: 714-721.
10. Bassaganya-Riera J, Pogranichniy RM, Jobgen SC, Halbur PG, Yoon KJ, et al. (2003) Conjugated linoleic acid ameliorates viral infectivity in a pig model of virally induced immunosuppression. J Nutr 133: 3204-3214.
11. Bassaganya-Riera J, Hontecillas R, (2006) CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 25: 454-465.
12. Bassaganya-Riera J, Guri AJ, Noble AM, Reynolds KA, King J, et al. (2007) Arachidonic acid-and docosahexaenoic acid-enriched formulas modulate antigen-specific T cell responses to influenza virus in neonatal piglets. Am J Clin Nutr 85: 824-836.
13. Bassaganya-Riera J, Misyak S, Guri AJ, Hontecillas R, (2009) PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. Cell Immunol 258: 138-146.
14. Bassaganya-Riera J, Hontecillas R, (2010) Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care.
15. Gorissen L, Raes K, Weckx S, Dannenberger D, Leroy F, et al. (2010) Production of conjugated linoleic acid and conjugated linolenic acid isomers by Bifidobacterium species. Appl Microbiol Biotechnol 87: 2257-2266.
16. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546.
17. Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, et al. (2009) Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 15: 760-768.
18. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, et al. (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202-1209, 1209 e1201.
19. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
20. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, et al. (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591.
21. Lawton EM, Ross RP, Hill C, Cotter PD, (2007) Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 7: 1236-1247.
22. Collado MC, Hernandez M, Sanz Y, (2005) Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. J Food Prot 68: 1034-1040.
23. Sun J, Le GW, Shi YH, Su GW, (2007) Factors involved in binding of Lactobacillus plantarum Lp6 to rat small intestinal mucus. Lett Appl Microbiol 44: 79-85.
24. Collado MC, Meriluoto J, Salminen S, (2007) Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 45: 454-460.
25. Drakes M, Blanchard T, Czinn S, (2004) Bacterial probiotic modulation of dendritic cells. Infect Immun 72: 3299-3309.
26. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, et al. (2008) Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14: 662-668.
27. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, et al. (2004) DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126: 1358-1373.
28. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, et al. (2010) Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A 107: 454-459.
29. Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, et al. (2011) Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 17: 289-297.
30. Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, et al. (2000) Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 119: 119-128.
31. Israel A, (2000) The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 10: 129-133.
32. Calder PC, (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52: 885-897.
33. Isaacs KL, Hontecillas R, Horne WT, Sandridge M, Herfarth H, et al. (2011) Pilot study of the effect of conjugated linoleic acid on the modulation of immune responses in patients with mild to moderately active Crohn's disease Washington D.C.
34. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, et al. (2001) An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96: 3323-3328.
35. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, et al. (2008) Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134: 688-695.
36. Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, et al. (2008) Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol 23: 1834-1839.
37. Bassaganya-Riera J, Hontecillas R, Zimmerman DR, Wannemuehler MJ, (2001) Dietary conjugated linoleic acid modulates phenotype and effector functions of porcine cd8(+) lymphocytes. J Nutr 131: 2370-2377.
38. Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, et al. (2011) Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 6: e22978.
39. Ewaschuk JB, Walker JW, Diaz H, Madsen KL, (2006) Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr 136: 1483-1487.